215 related articles for article (PubMed ID: 3839120)
1. In vitro activity of BMY-28142 in comparison with those of other beta-lactam antimicrobial agents.
Tsuji A; Maniatis A; Bertram MA; Young LS
Antimicrob Agents Chemother; 1985 Apr; 27(4):515-9. PubMed ID: 3839120
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin.
Fuchs PC; Jones RN; Barry AL; Thornsberry C
Antimicrob Agents Chemother; 1985 May; 27(5):679-82. PubMed ID: 3893316
[TBL] [Abstract][Full Text] [Related]
3. Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics.
Kessler RE; Bies M; Buck RE; Chisholm DR; Pursiano TA; Tsai YH; Misiek M; Price KE; Leitner F
Antimicrob Agents Chemother; 1985 Feb; 27(2):207-16. PubMed ID: 3885849
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the in vitro antimicrobial activity of cefepime compared to other broad-spectrum beta-lactams tested against recent clinical isolates from 10 Chinese hospitals. Chinese Antimicrobial Resistance Study Group.
Xu Y; Chen M; Biedenbach DJ; Deshpande LM; Jones RN
Diagn Microbiol Infect Dis; 1999 Oct; 35(2):135-42. PubMed ID: 10579094
[TBL] [Abstract][Full Text] [Related]
5. The activity of BMY 28142 a new broad spectrum beta-lactamase stable cephalosporin.
Neu HC; Chin NX; Jules K; Labthavikul P
J Antimicrob Chemother; 1986 Apr; 17(4):441-52. PubMed ID: 3486862
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Japan Antimicrobial Resistance Study Group.
Yamaguchi K; Mathai D; Biedenbach DJ; Lewis MT; Gales AC; Jones RN
Diagn Microbiol Infect Dis; 1999 Jun; 34(2):123-34. PubMed ID: 10354863
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility of gentamicin sensitive and resistant gram negative bacilli to ceftazidime.
Bremner DA
Pathology; 1987 Jul; 19(3):274-6. PubMed ID: 3124067
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of carumonam (RO 17-2301), BMY-28142, aztreonam, and ceftazidime against 7,620 consecutive clinical bacterial isolates.
Fuchs PC; Jones RN; Barry AL; Ayers LW; Gavan TL; Gerlach EH
Diagn Microbiol Infect Dis; 1986 Nov; 5(4):345-9. PubMed ID: 3536278
[TBL] [Abstract][Full Text] [Related]
9. Multicenter evaluation of antimicrobial resistance to six broad-spectrum beta-lactams in Colombia using the Etest method. The Colombian Antimicrobial Resistance Study Group.
Jones RN; Salazar JC; Pfaller MA; Doern GV
Diagn Microbiol Infect Dis; 1997 Dec; 29(4):265-72. PubMed ID: 9458984
[TBL] [Abstract][Full Text] [Related]
10. In vitro evaluation of cefepime and other broad-spectrum beta-lactams against bacteria from Indonesian medical centers. The Indonesia Antimicrobial Resistance Study Group.
Lewis MT; Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 1999 Dec; 35(4):285-90. PubMed ID: 10668587
[TBL] [Abstract][Full Text] [Related]
11. Comparative in vitro evaluation of BMY-28142, a new broad-spectrum cephalosporin, versus other beta-lactams against multiresistant gram-negative isolates.
Giamarellou H; Sahin A; Chryssouli Z
Drugs Exp Clin Res; 1987; 13(3):149-53. PubMed ID: 3622243
[TBL] [Abstract][Full Text] [Related]
12. Comparative activities of the oxa-beta-lactam LY127935, cefotaxime, cefoperazone, cefamandole, and ticarcillin against multiply resistant gram-negative bacilli.
Hall WH; Opfer BJ; Gerding DN
Antimicrob Agents Chemother; 1980 Feb; 17(2):273-9. PubMed ID: 6247970
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2008 May; 61(1):86-95. PubMed ID: 18385000
[TBL] [Abstract][Full Text] [Related]
14. In vitro antibacterial activity of BMY-28142, a new extended-spectrum cephalosporin.
Vuye A; Pijck J
Antimicrob Agents Chemother; 1985 Apr; 27(4):574-7. PubMed ID: 3859244
[TBL] [Abstract][Full Text] [Related]
15. BMY-28100, a new oral cephalosporin: antimicrobial activity against nearly 7,000 recent clinical isolates, comparative potency with other oral agents, and activity against beta-lactamase producing isolates.
Jones RN; Barry AL
Diagn Microbiol Infect Dis; 1988 Jan; 9(1):11-26. PubMed ID: 3259489
[TBL] [Abstract][Full Text] [Related]
16. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
[TBL] [Abstract][Full Text] [Related]
17. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
18. The in-vivo antibacterial activity of ceftazidime (Gr 20263)--a comparison with other new beta-lactam antibiotics and gentamicin.
Acred P; Ryan DM; Sowa MA; Watts CM
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():247-55. PubMed ID: 19802994
[TBL] [Abstract][Full Text] [Related]
19. In vitro evaluation of cefepime and other broad-spectrum beta-lactams in Taiwan medical centers. The Taiwan Antimicrobial Resistance Study Group.
Biedenbach DJ; Johnson DM; Jones RN
Diagn Microbiol Infect Dis; 1999 Dec; 35(4):299-305. PubMed ID: 10668589
[TBL] [Abstract][Full Text] [Related]
20. Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.
Jones RN; Barry AL; Thornsberry C; Gerlach EH; Fuchs PC; Gavan TL; Sommers HM
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():187-211. PubMed ID: 19802985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]